Skip to Content

Multiple Sclerosis Clinical Trials

AN OBSERVATIONAL STUDY OF OCRELIZUMAB-TREATED PATIENTS WITH MULTIPLE SCLEROSIS TO DETERMINE THE INCIDENCE AND MORTALITY RATES OF BREAST CANCER AND ALL MALIGNANCIES (VERISMO STUDY)
Aims: The purpose of this study is to assess and characterize the incidence and mortality rates of breast cancer, all malignancies, and the long-term safety regarding serious adverse events (SAEs) among patients with multiple sclerosis (MS) newly exposed to the medication ocrelizumab, (OCREVUS®) under routine clinical care.
Principal Investigator: Afif Hentati, MD
NorthShore Project Number: EH20-012
Contact: Call 847.503.4044 with questions regarding the study.
Open to enrollment: Yes

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Aims: The purpose of this study is to characterize the efficacy and safety of evobrutinib 45 mg administered orally twice daily versus teriflunomide (Aubagio®; 14 mg once a day orally) in participants with Relapsing Multiple Sclerosis by evaluation of MRI parameters and other clinical measurements.  The study also aims to assess the relationship between subject disease biomarker and disease activity or treatment response.
Principal Investigator: Afif Hentati, MD
NorthShore Project Number: EH20-240
Contact: Call 847.503.4044 with questions regarding the study.
Open to enrollment: Yes